Humacyte Inc
NASDAQ:HUMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fuso Chemical Co Ltd
TSE:4368
|
JP |
|
T
|
Trikomsel Oke Tbk PT
IDX:TRIO
|
ID |
|
Banka BioLoo Ltd
NSE:BANKA
|
IN |
|
Newton Golf Co
NASDAQ:NWTG
|
US |
|
Rheinmetall AG
XETRA:RHM
|
DE |
|
J
|
J-Max Co Ltd
TSE:3422
|
JP |
|
C
|
Ching Feng Home Fashions Co Ltd
TWSE:9935
|
TW |
|
Ming Yuan Cloud Group Holdings Ltd
HKEX:909
|
CN |
|
S
|
SBM Offshore NV
VSE:SBMO
|
NL |
|
O
|
Osisko Green Acquisition Ltd
TSX:GOGR
|
CA |
|
Kaveri Seed Company Ltd
NSE:KSCL
|
IN |
|
Samsonite International SA
HKEX:1910
|
LU |
|
Britannia Industries Ltd
NSE:BRITANNIA
|
IN |
|
China Innovation Investment Ltd
HKEX:1217
|
HK |
|
Nippon Chemical Industrial Co Ltd
TSE:4092
|
JP |
|
CTT Systems AB
STO:CTT
|
SE |
|
I
|
Infinity Development Holdings Company Ltd
HKEX:640
|
MO |
|
E
|
Enish Inc
TSE:3667
|
JP |
|
Vaibhav Global Ltd
NSE:VAIBHAVGBL
|
IN |
|
L
|
Labixiaoxin Snacks Group Ltd
HKEX:1262
|
CN |
|
Alkali Metals Ltd
NSE:ALKALI
|
IN |
|
Motilal Oswal Financial Services Ltd
NSE:MOTILALOFS
|
IN |
Humacyte Inc
Total Receivables
Humacyte Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Humacyte Inc
NASDAQ:HUMA
|
Total Receivables
$441k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$2.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Humacyte Inc
Glance View
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
See Also
What is Humacyte Inc's Total Receivables?
Total Receivables
441k
USD
Based on the financial report for Dec 31, 2025, Humacyte Inc's Total Receivables amounts to 441k USD.
What is Humacyte Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
35%
